Cancer

Feb 02, 2017

ALCMI, ALCF and Scancell partner to evaluate SCIB2 cancer vaccine for NSCLC The Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J. Addario Lung Cancer Foundation (ALCF) have collaborated with UK-based Scancell to assess SCIB2 cancer vaccine to treat patients with non-small-cell lung cancer (NSCLC). SCIB...

Dec 16, 2016

Cancer, a highly morbid disease, has one of the worst incidence and mortality statistics across the globe. As reported by the American Cancer Society, the estimated annual incidence for 2016 has crossed 40,000 cases or more in USA alone. In the statistics, the most common type of cancer is breast cancer, with around...

Nov 30, 2016

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is s...

Nov 17, 2016

Phosphoinositide 3-kinases (PI3Ks) were discovered in 1980, and since then drug developers have accelerated their research funds in order to find potential drug candidate for inhibiting PI3Ks for the treatment of cancers. Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that act as intermediate signaling mol...

Oct 10, 2016

Clinicians have been conducting biopsies for a long time, for diagnosing and managing cancer, as genetic profile of tumor is analyzed through biopsy. Tissue biopsy is a traditional biopsy technique which is a time consuming and lengthy procedure, and cannot be performed routinely. Liquid Biopsy is a next generation ...

Sep 15, 2016

Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to the results of Phase III data, and has also shown great stats that could prove that it might have an edge in the hotly co...

Sep 14, 2016

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Sep 09, 2016

There might be many treatment options for a cancer patients, but each one has its limitations. Also, a physician has a challenge in determining the best treatment method for an individual. However, a research team from Berkeley Lab has devised a system by which these decision are easier to make based in the genetic ...

Sep 01, 2016

There has been a shocking revelation in a report published in Science Translational Medicine by Bengt Westermark, a tumour biologist at Uppsala, who reports that a cell line widely used to study brain cancer does not match the cells used to create the line nearly 50 years ago, or the tumour supposed to be its source...

Aug 24, 2016

Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer...